|
Our company has a 50-year heritage of serving both the
National Health Service (NHS) and private health sectors within the
UK and Republic of Ireland. In the last ten years the company has
achieved considerable growth. The philosophy of the group is to
further build upon our success within the secondary care sector.
This will include the focus on the development of niche branded
products.
In
line with this we have signed for the exclusive rights to market a
new chemical entity for a respiratory/cardiology condition set to
revolutionise treatment in its field. This product is branded as
Remodulin, which is now licensed in the US and is currently awaiting
EMEA approval.
In
line with this we have signed for the exclusive rights to market a
new chemical entity for a respiratory/cardiology condition set to
revolutionise treatment in its field. This product is Remodulin,
which is now licensed in the US and is currently awaiting EMEA
approval. |
Goldshield Group plc acquired
Antigen Pharmaceuticals in November 2001, with a vision to develop
our niche concept within the secondary care sector. We now have the
support and infrastructure to grow to meet the challenges of
business development in the United Kingdom, Western Europe and the
Rest Of The World.
As
one of the largest suppliers of small volume parenteral products to
the UK National Health Service we have a reputation of modifying
established products to ensure safer administration and more
appropriate presentations. This has included initiatives from safer
labelling & packaging formats through to innovative new
presentations of products, such as our bupivacaine infusion
solution, which was the first product licensed to cater for the
trend towards continuous postoperative epidural infusions and mobile
epidurals during labour, utilising lower concentrations of the
drug.
In 1996 we acquired the UK & Irish rights to two
branded pharmaceuticals - Robinul and Dopram - from Wyeth
Laboratories. We have successfully re-launched and marketed them to
UK hospital specialists turning around one respiratory product
(doxapram) in major decline due to new technologies.
|
Through our hospital-focused sales team we distribute high
quality, value-added products to compliment our activity in certain
markets - such as anaesthetics, pain, oncology, and respiratory
medicine.
It is our firm belief that Antigen is
the best placed company in the UK to promote niche hospital products
as our current team has considerable experience and expertise that
makes us the ideal partner to maximise the potential for new
chemical entities in the UK market. We would also consider the
options for other European territories, as our development plan,
fully backed by our parent company, is strongly focused on future
growth outside of the UK & Ireland.
|
